TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01323972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
Description: 4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
Description: 4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
Description: 4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
Description: 4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
Study: NCT03229070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval effort group
Description: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous effort group
Description: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
Study: NCT00060762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: 20 sessions of interpersonal therapy were provided over a 6-month period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Treatment
Description: 20 sessions of behavioral weight loss treatment were provided over a 6-month period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self Help
Description: 10 sessions of guided self help were provided over a 6-month period
Study: NCT03347097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1-TIL
Study: NCT00609817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib/Dexamethasone
Description: Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
Study: NCT03258255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: penil or pudendal nerve block in circumcision
Description: regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: penil or pudendal nerve block in circumcision
Description: regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
Study: NCT03328988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
Study: NCT01252368

Intervention type: BIOLOGICAL
Intervention: hypertension
Description: patients taking daily ACE inhibitors or sartanes
Study: NCT03353077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT03022409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib is an oral agent and will be dosed at 160 mg. Ceralasertib tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents.
Study: NCT03900364

Intervention type: PROCEDURE
Group type: OTHER
Intervention: partial nephrectomy
Description: Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: partial nephrectomy
Description: Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
Study: NCT02965677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Releasing Peripheral Balloon Dilatation Catheter
Description: in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Balloon Dilatation Catheter
Description: in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
Study: NCT03415516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gluma Universal
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gluma Universal
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gluma Universal
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All Bond Universal
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All Bond Universal
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All Bond Universal
Description: Adhesive systems

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Bond2
Description: Adhesive systems
Study: NCT01217996

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized working memory training program (intervention)
Description: A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized working memory training program (control)
Description: Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
Study: NCT01988324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDHT-PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT-scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Study: NCT01418469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caseinate
Description: 18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: 18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: 18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy+BCAA
Description: 18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
Study: NCT02785211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment
Description: The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Activation Treatment
Description: The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
Study: NCT04615936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylene-Blue Photodisinfection
Description: Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
Study: NCT00614835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Gemcitabine
Description: Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
Study: NCT00299858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline
Description: Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time.
Study: NCT03371914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Management training and data feedback
Description: The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
Study: NCT01780623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright white light

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim red light
Study: NCT02497469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab placebo
Description: Adalimumab placebo-matching injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab placebo
Description: Vedolizumab placebo-matching infusion
Study: NCT01969526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
Study: NCT04942262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denture adhesive (Polident®, GlaxoSmithKline, Ireland)
Description: cream-type denture adhesive available as an over-the-counter product in Thailand
Study: NCT02818504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wize Mirror
Description: Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wize Mirror
Description: Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
Study: NCT00919880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin+ paclitaxel
Description: carboplatin AUC 2mg/mL\*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
Study: NCT02075125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Description: Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Description: Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
Study: NCT00686972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
Study: NCT01901185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept / Autoinjector A
Description: Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
Study: NCT02524119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
Study: NCT03555799

Intervention type: DIAGNOSTIC_TEST
Intervention: Inferior vena cava ultrasound
Description: Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
Study: NCT03453294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation using THRIVE
Description: Apnoeic oxygenation using THRIVE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation and mechanical ventilation
Description: Endotracheal intubation and mechanical ventilation
Study: NCT02192788

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy for Oligometastases
Study: NCT00591877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~* ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~* PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~* CV-12: 4 finger breadths superior to the umbilicus.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: The acupoints for SAC are:~* LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~* GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~* UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
Study: NCT04376281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Description: Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
Study: NCT05068843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic partial meniscectomy
Description: In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy
Description: The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
Study: NCT00216255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagoclone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03470922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT01231217

Intervention type: OTHER
Group type: OTHER
Intervention: Green tea (Camellia sinensis)
Description: Patients are recommended to drink at least 5 cups of green tea per day

Intervention type: OTHER
Group type: OTHER
Intervention: Coffee
Description: Patients are recommended to drink as much coffee as they tolerate.
Study: NCT00197678

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins-Multiples of RDA
Description: 20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins-Single RDA
Description: 1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery